<p>GWN Securities Inc. 在最近向證券交易委員會提交的 13F 文件中表示，在第三季度減少了對強生（NYSE:JNJ - 免費報告）股票的持有，減幅為 51.6%。該基金在此期間出售了 27,326 股後，持有該公司 25,658 股股票。強生大約佔 GWN Securities Inc. 投資組合的 1.1%，是其第 14 大持股。截止最近一個季度，GWN Securities Inc. 在強生的持股價值為 4,790,000 美元。</p>
<p>獲取 <strong>強生</strong> 的提醒：</p>
<ul>
<li>這隻 ETF 證明了醫療保健反彈是真實的</li>
</ul>
<p>其他機構投資者和對沖基金最近也增加或減少了對該公司的投資。先鋒集團（Vanguard Group Inc.）在第二季度增持了 1.3% 的強生股份。先鋒集團目前擁有 237,047,859 股該公司的股票，價值 36,209,060,000 美元，在上個季度又增持了 3,085,180 股。Geode Capital Management LLC 在第二季度將其在強生的持股提高了 2.1%。Geode Capital Management LLC 目前擁有 60,609,476 股該公司的股票，價值 9,227,988,000 美元，在上個季度又購買了 1,225,676 股。挪威銀行（Norges Bank）在第二季度獲得了強生的新股份，價值約為 4,877,174,000 美元。紐約梅隆銀行（Bank of New York Mellon Corp）在第二季度增持了 2.7% 的強生股份。紐約梅隆銀行目前擁有 23,802,503 股該公司的股票，價值 3,635,832,000 美元，在上個季度又購買了 620,039 股。最後，查爾斯·施瓦布投資管理公司（Charles Schwab Investment Management Inc.）在第二季度將其在強生的持股提高了 0.3%。查爾斯·施瓦布投資管理公司目前擁有 18,951,337 股該公司的股票，價值 2,894,979,000 美元，在上個季度又購買了 52,074 股。目前，69.55% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>分析師評級調整</h2>
<p>幾位股票研究分析師最近對 JNJ 股票發表了評論。BMO Capital Markets 在 12 月 11 日的研究報告中重申了對強生股票的 &#34;跑贏大盤&#34; 評級。Stifel Nicolaus 在 10 月 15 日的研究報告中將強生的目標價從 165.00 美元上調至 190.00 美元，並給予該股票 &#34;持有&#34; 評級。瑞銀集團（UBS Group）在 1 月 5 日的研究報告中重申了對強生股票的 &#34;買入&#34; 評級。加拿大皇家銀行（Royal Bank Of Canada）在 12 月 17 日的報告中設定了強生的目標價為 240.00 美元。最後，摩根士丹利（Morgan Stanley）在 12 月 12 日的報告中將強生的目標價從 190.00 美元上調至 197.00 美元，並給予該股票 &#34;等權重&#34; 評級。四位投資分析師對該股票給予了強烈買入評級，十五位給予了買入評級，九位給予了持有評級。根據 MarketBeat 的數據，強生目前的共識評級為 &#34;適度買入&#34;，平均目標價為 213.33 美元。</p>
<ul>
<li>降息使這三隻收益 ETF 比以往更具吸引力</li>
</ul>
<p><strong>查看我們最新的 JNJ 股票報告</strong></p>
<h2>強生股票表現</h2>
<p>NYSE JNJ 週五開盤價為 218.81 美元。該公司的市值為 5271.8 億美元，市盈率為 21.12，市盈增長比率為 2.26，貝塔值為 0.34。該股票的 50 日簡單移動平均線為 205.82 美元，200 日簡單移動平均線為 186.74 美元。公司的債務與股本比率為 0.50，速動比率為 0.80，流動比率為 1.07。強生的 52 周低點為 141.50 美元，52 周高點為 220.11 美元。</p>
<ul>
<li>輝瑞增加對減肥藥的重大投資</li>
</ul>
<p>強生（NYSE:JNJ - 獲取免費報告）在 10 月 14 日星期二發佈了其財報。該公司報告本季度每股收益為 2.80 美元，超出市場共識預期的 2.76 美元，超出 0.04 美元。該公司本季度的收入為 239.9 億美元，而分析師預期為 237.3 億美元。強生的股本回報率為 32.73%，淨利潤率為 27.26%。強生本季度的收入同比增長 6.8%。去年同期，該公司每股收益為 2.42 美元。平均而言，股票分析師預測強生在當前年度的每股收益將達到 10.58 美元。</p>
<h2>強生股息公告</h2>
<p>該公司最近還披露了季度股息，將於 3 月 10 日星期二支付。記錄在案的股東將在 2 月 24 日星期二獲得 1.30 美元的股息。這代表着 5.20 美元的年化股息和 2.4% 的收益率。除息日期為 2 月 24 日星期二。強生的股息支付比率目前為 50.19%。</p>
<h2>關於強生</h2>
<p>（免費報告）</p>
<p>強生是一家總部位於新澤西州新布倫瑞克的跨國醫療保健公司，開發、生產和銷售廣泛的產品，涵蓋製藥、醫療設備和以前的消費健康。該公司由約翰遜家族於 1886 年創立，已發展成為一個在全球多個國家開展業務和銷售的全球醫療保健組織。</p>
<p>該公司的製藥業務主要在其揚森研究與開發組織下運作，專注於免疫學、傳染病、腫瘤學和神經科學等治療領域的處方藥。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過強生</li>
<li>埃隆將 SpaceX 公開上市！$100 的 IPO 前機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>執行命令 14330：特朗普最大的一次</li>
<li>用這四個簡單步驟 “防止美聯儲影響” 您的銀行賬户</li>
</ul>
<p><strong>想知道其他對 JNJ 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Johnson &amp; Johnson (NYSE:JNJ - 免費報告) 的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Johnson &amp; Johnson 嗎？</h2>
<p>在考慮 Johnson &amp; Johnson 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Johnson &amp; Johnson 並不在名單上。</p>
<p>雖然 Johnson &amp; Johnson 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

強生

<p>GWN Securities Inc. 在第三季度減少了對強生（NYSE: JNJ）51.6% 的持股，目前持有 25,658 股，價值為 479 萬美元。其他機構投資者如先鋒集團和 Geode Capital 則增加了他們的股份。分析師們維持 “適度買入” 的共識評級，平均目標價為 213.33 美元。強生的股票開盤價為 218.81 美元，市值為 5271.8 億美元，最近的每股收益為 2.80 美元，超出預期。該公司報告的收入同比增長 6.8%</p>

<p>GWN Securities Inc. lessened its holdings in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 51.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,658 shares of the company's stock after selling 27,326 shares during the period. Johnson &amp; Johnson makes up about 1.1% of GWN Securities Inc.'s portfolio, making the stock its 14th biggest holding. GWN Securities Inc.'s holdings in Johnson &amp; Johnson were worth $4,790,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>GWN Securities Inc. 在最近向證券交易委員會提交的 13F 文件中表示，在第三季度減少了對強生（NYSE:JNJ - 免費報告）股票的持有，減幅為 51.6%。該基金在此期間出售了 27,326 股後，持有該公司 25,658 股股票。強生大約佔 GWN Securities Inc. 投資組合的 1.1%，是其第 14 大持股。截止最近一個季度，GWN Securities Inc. 在強生的持股價值為 4,790,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>強生</strong> 的提醒：</p>
</div><ul>
<li>This ETF Is Proof That the Healthcare Rebound Is Real</li>
</ul>
<div class="lb-trans"><ul>
<li>這隻 ETF 證明了醫療保健反彈是真實的</li>
</ul>
</div><p>Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Johnson &amp; Johnson by 1.3% in the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company's stock worth $36,209,060,000 after acquiring an additional 3,085,180 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Johnson &amp; Johnson by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company's stock valued at $9,227,988,000 after purchasing an additional 1,225,676 shares during the last quarter. Norges Bank acquired a new stake in Johnson &amp; Johnson in the 2nd quarter worth approximately $4,877,174,000. Bank of New York Mellon Corp boosted its stake in Johnson &amp; Johnson by 2.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company's stock worth $3,635,832,000 after purchasing an additional 620,039 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Johnson &amp; Johnson by 0.3% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company's stock worth $2,894,979,000 after purchasing an additional 52,074 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金最近也增加或減少了對該公司的投資。先鋒集團（Vanguard Group Inc.）在第二季度增持了 1.3% 的強生股份。先鋒集團目前擁有 237,047,859 股該公司的股票，價值 36,209,060,000 美元，在上個季度又增持了 3,085,180 股。Geode Capital Management LLC 在第二季度將其在強生的持股提高了 2.1%。Geode Capital Management LLC 目前擁有 60,609,476 股該公司的股票，價值 9,227,988,000 美元，在上個季度又購買了 1,225,676 股。挪威銀行（Norges Bank）在第二季度獲得了強生的新股份，價值約為 4,877,174,000 美元。紐約梅隆銀行（Bank of New York Mellon Corp）在第二季度增持了 2.7% 的強生股份。紐約梅隆銀行目前擁有 23,802,503 股該公司的股票，價值 3,635,832,000 美元，在上個季度又購買了 620,039 股。最後，查爾斯·施瓦布投資管理公司（Charles Schwab Investment Management Inc.）在第二季度將其在強生的持股提高了 0.3%。查爾斯·施瓦布投資管理公司目前擁有 18,951,337 股該公司的股票，價值 2,894,979,000 美元，在上個季度又購買了 52,074 股。目前，69.55% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>Several equities research analysts have recently commented on JNJ shares. BMO Capital Markets reiterated an &#34;outperform&#34; rating on shares of Johnson &amp; Johnson in a research note on Thursday, December 11th. Stifel Nicolaus raised their target price on Johnson &amp; Johnson from $165.00 to $190.00 and gave the stock a &#34;hold&#34; rating in a research note on Wednesday, October 15th. UBS Group reaffirmed a &#34;buy&#34; rating on shares of Johnson &amp; Johnson in a research report on Monday, January 5th. Royal Bank Of Canada set a $240.00 price objective on Johnson &amp; Johnson in a report on Wednesday, December 17th. Finally, Morgan Stanley lifted their target price on Johnson &amp; Johnson from $190.00 to $197.00 and gave the stock an &#34;equal weight&#34; rating in a report on Friday, December 12th. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Johnson &amp; Johnson currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $213.33.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對 JNJ 股票發表了評論。BMO Capital Markets 在 12 月 11 日的研究報告中重申了對強生股票的 &#34;跑贏大盤&#34; 評級。Stifel Nicolaus 在 10 月 15 日的研究報告中將強生的目標價從 165.00 美元上調至 190.00 美元，並給予該股票 &#34;持有&#34; 評級。瑞銀集團（UBS Group）在 1 月 5 日的研究報告中重申了對強生股票的 &#34;買入&#34; 評級。加拿大皇家銀行（Royal Bank Of Canada）在 12 月 17 日的報告中設定了強生的目標價為 240.00 美元。最後，摩根士丹利（Morgan Stanley）在 12 月 12 日的報告中將強生的目標價從 190.00 美元上調至 197.00 美元，並給予該股票 &#34;等權重&#34; 評級。四位投資分析師對該股票給予了強烈買入評級，十五位給予了買入評級，九位給予了持有評級。根據 MarketBeat 的數據，強生目前的共識評級為 &#34;適度買入&#34;，平均目標價為 213.33 美元。</p>
</div><ul>
<li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li>
</ul>
<div class="lb-trans"><ul>
<li>降息使這三隻收益 ETF 比以往更具吸引力</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on JNJ</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 JNJ 股票報告</strong></p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>強生股票表現</h2>
</div><p>NYSE JNJ opened at $218.81 on Friday. The firm has a market capitalization of $527.18 billion, a P/E ratio of 21.12, a PEG ratio of 2.26 and a beta of 0.34. The stock has a 50-day simple moving average of $205.82 and a two-hundred day simple moving average of $186.74. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson &amp; Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $220.11.</p>
<div class="lb-trans"><p>NYSE JNJ 週五開盤價為 218.81 美元。該公司的市值為 5271.8 億美元，市盈率為 21.12，市盈增長比率為 2.26，貝塔值為 0.34。該股票的 50 日簡單移動平均線為 205.82 美元，200 日簡單移動平均線為 186.74 美元。公司的債務與股本比率為 0.50，速動比率為 0.80，流動比率為 1.07。強生的 52 周低點為 141.50 美元，52 周高點為 220.11 美元。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>輝瑞增加對減肥藥的重大投資</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 14th. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.76 by $0.04. The firm had revenue of $23.99 billion for the quarter, compared to analyst estimates of $23.73 billion. Johnson &amp; Johnson had a return on equity of 32.73% and a net margin of 27.26%.Johnson &amp; Johnson's revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period last year, the company earned $2.42 earnings per share. On average, equities analysts forecast that Johnson &amp; Johnson will post 10.58 earnings per share for the current year.</p>
<div class="lb-trans"><p>強生（NYSE:JNJ - 獲取免費報告）在 10 月 14 日星期二發佈了其財報。該公司報告本季度每股收益為 2.80 美元，超出市場共識預期的 2.76 美元，超出 0.04 美元。該公司本季度的收入為 239.9 億美元，而分析師預期為 237.3 億美元。強生的股本回報率為 32.73%，淨利潤率為 27.26%。強生本季度的收入同比增長 6.8%。去年同期，該公司每股收益為 2.42 美元。平均而言，股票分析師預測強生在當前年度的每股收益將達到 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Dividend Announcement</h2>
<div class="lb-trans"><h2>強生股息公告</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.4%. The ex-dividend date is Tuesday, February 24th. Johnson &amp; Johnson's dividend payout ratio is currently 50.19%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度股息，將於 3 月 10 日星期二支付。記錄在案的股東將在 2 月 24 日星期二獲得 1.30 美元的股息。這代表着 5.20 美元的年化股息和 2.4% 的收益率。除息日期為 2 月 24 日星期二。強生的股息支付比率目前為 50.19%。</p>
</div><h2>About Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>關於強生</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Johnson &amp; Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.</p>
<div class="lb-trans"><p>強生是一家總部位於新澤西州新布倫瑞克的跨國醫療保健公司，開發、生產和銷售廣泛的產品，涵蓋製藥、醫療設備和以前的消費健康。該公司由約翰遜家族於 1886 年創立，已發展成為一個在全球多個國家開展業務和銷售的全球醫療保健組織。</p>
</div><p>The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.</p>
<div class="lb-trans"><p>該公司的製藥業務主要在其揚森研究與開發組織下運作，專注於免疫學、傳染病、腫瘤學和神經科學等治療領域的處方藥。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過強生</li>
<li>埃隆將 SpaceX 公開上市！$100 的 IPO 前機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>執行命令 14330：特朗普最大的一次</li>
<li>用這四個簡單步驟 “防止美聯儲影響” 您的銀行賬户</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對 JNJ 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Johnson &amp; Johnson (NYSE:JNJ - 免費報告) 的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Johnson &amp; Johnson 嗎？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Johnson &amp; Johnson 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Johnson &amp; Johnson 並不在名單上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Johnson &amp; Johnson 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

GWN Securities Inc. 出售了強生 $JNJ 的股票